ATE545434T1 - Stabilisierte zusammensetzungen - Google Patents

Stabilisierte zusammensetzungen

Info

Publication number: ATE545434T1
Authority: AT; Austria
Prior art keywords: bare; protein; class; compositions; stabilization
Prior art date: 2003-10-23

Application number

AT04796096T

Other languages

English (en)

Inventor

Claudia Magagnoli

Maurizio Morandi

Original Assignee

Novartis Vaccines & Diagnostic

Claudia Magagnoli

Maurizio Morandi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-23

Filing date

2004-10-22

Publication date

2012-03-15

2004-10-22 Application filed by Novartis Vaccines & Diagnostic, Claudia Magagnoli, Maurizio Morandi filed Critical Novartis Vaccines & Diagnostic

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE545434T1 publication Critical patent/ATE545434T1/de

Links

239000000203 mixture Substances 0.000 title abstract 5
108090000623 proteins and genes Proteins 0.000 abstract 4
102000004169 proteins and genes Human genes 0.000 abstract 4
238000000034 method Methods 0.000 abstract 2
230000006641 stabilisation Effects 0.000 abstract 2
238000011105 stabilization Methods 0.000 abstract 2
OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical class C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract 1
108010077805 Bacterial Proteins Proteins 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)

AT04796096T 2003-10-23 2004-10-22 Stabilisierte zusammensetzungen ATE545434T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US51430703P	2003-10-23	2003-10-23
US56199904P	2004-04-13	2004-04-13
PCT/US2004/035039 WO2005042016A2 (en)	2003-10-23	2004-10-22	Stabilised compositions

Publications (1)

Publication Number	Publication Date
ATE545434T1 true ATE545434T1 (de)	2012-03-15

Family

ID=34555932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04796096T ATE545434T1 (de)	2003-10-23	2004-10-22	Stabilisierte zusammensetzungen

Country Status (7)

Country	Link
US (1)	US7883709B2 (de)
EP (1)	EP1675869B1 (de)
JP (2)	JP2007509164A (de)
AT (1)	ATE545434T1 (de)
CA (1)	CA2542777C (de)
ES (1)	ES2379267T3 (de)
WO (1)	WO2005042016A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9326174D0 (en) *	1993-12-22	1994-02-23	Biocine Sclavo	Mucosal adjuvant
CA2730760A1 (en) *	2008-07-16	2010-01-21	Surmodics Pharmaceuticals, Inc.	Process for preparing microparticles containing bioactive peptides
EP2793939A1 (de) *	2011-12-23	2014-10-29	Novartis AG	Stabile zusammensetzungen zur immunisierung gegen staphylococcus aureus
TWI694836B (zh) *	2014-05-16	2020-06-01	英商葛蘭素史克智慧財產管理有限公司	抗體調配物
KR102021605B1 (ko) *	2015-02-13	2019-09-16	주식회사 씨젠	다중타겟 핵산서열 증폭반응용 조성물의 동결건조 방법
KR102200618B1 (ko) *	2018-01-12	2021-01-08	재단법인대구경북과학기술원	설포베타인계 쯔비터이온성 계면활성제를 포함하는 생물학적 분자의 조직침투용 조성물 및 이의 용도
AU2022283271A1 (en)	2021-05-24	2023-12-07	Provention Bio, Inc.	Methods for treating type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816440A (en) *	1985-09-26	1989-03-28	Cetus Corporation	Stable formulation of biologically active proteins for parenteral injection
US20020044939A1 (en) *	1991-12-31	2002-04-18	Chiron S.P.A.	Immunogenic detoxified mutants of cholera toxin
JP3687993B2 (ja) *	1994-06-24	2005-08-24	シスメックス株式会社	インシュリン標準液
GB9614718D0 (en) *	1996-07-12	1996-09-04	Bayer Ag	3-ureido-pyridofurans and -pyridothiophenes
US6818222B1 (en) *	1997-03-21	2004-11-16	Chiron Corporation	Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
WO2000071154A2 (de) *	1999-05-20	2000-11-30	Pharmasol Gmbh	Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort
EP2292263A3 (de)	1999-12-02	2011-07-27	Novartis Vaccines and Diagnostics, Inc.	Zusammensetzungen und methoden zur stabilisierung von biologischen Molekülen nach Lyophilisierung
WO2002092125A1 (en) *	2001-05-11	2002-11-21	Novartis Ag	Compositions for use in treating ige-associated disorders
US7229645B2 (en)	2001-06-08	2007-06-12	Powderject Research Limited	Spray freeze-dried compositions

2004
- 2004-10-22 JP JP2006536824A patent/JP2007509164A/ja not_active Withdrawn
- 2004-10-22 CA CA2542777A patent/CA2542777C/en not_active Expired - Fee Related
- 2004-10-22 EP EP04796096A patent/EP1675869B1/de not_active Expired - Lifetime
- 2004-10-22 US US10/576,732 patent/US7883709B2/en not_active Expired - Fee Related
- 2004-10-22 ES ES04796096T patent/ES2379267T3/es not_active Expired - Lifetime
- 2004-10-22 WO PCT/US2004/035039 patent/WO2005042016A2/en not_active Ceased
- 2004-10-22 AT AT04796096T patent/ATE545434T1/de active
2010
- 2010-12-28 JP JP2010294238A patent/JP5784306B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2005042016A2 (en)	2005-05-12
US7883709B2 (en)	2011-02-08
CA2542777C (en)	2016-02-02
EP1675869B1 (de)	2012-02-15
CA2542777A1 (en)	2005-05-12
US20070110809A1 (en)	2007-05-17
WO2005042016A3 (en)	2005-06-30
EP1675869A2 (de)	2006-07-05
JP2011132234A (ja)	2011-07-07
ES2379267T3 (es)	2012-04-24
JP2007509164A (ja)	2007-04-12
JP5784306B2 (ja)	2015-09-24

Publication	Publication Date	Title
TW200745334A (en)	2007-12-16	Compositions and methods for producing a composition
ATE548374T1 (de)	2012-03-15	2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
MXPA05003730A (es)	2005-12-14	Eritropoyetina: remodelado y glicoconjugacion de eritropoyetina.
CY1106682T1 (el)	2012-05-23	Ενωση λακταμης
SG130189A1 (en)	2007-03-20	Substituted indole-o-glucosides
ATE534383T1 (de)	2011-12-15	Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
IL211367A0 (en)	2011-04-28	An antibody, a fragment thereof, a method of preparing the same and a use of the antibody
UA86042C2 (en)	2009-03-25	Substituted indazole-o-glucosides
MX2009013199A (es)	2010-01-15	Anticuerpos anti-notch1 nnr y sus metodos de uso.
TNSN07222A1 (en)	2008-11-21	Nematicidal compositions
WO2005012242A3 (en)	2005-11-17	Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
CY1109998T1 (el)	2014-09-10	Ενδυναμωτες υποδοχεων γλουταμινικου
CY1113199T1 (el)	2016-04-13	Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
TW200732349A (en)	2007-09-01	Anti-OX40L antibodies and methods using same
WO2004099231A3 (en)	2006-03-16	Glycopegylation methods and proteins/peptides produced by the methods
BRPI0518334A2 (pt)	2008-11-11	composiÇço de revestimento, mÉtodo de revestimento, revestimento, e, mÉtodo para preparar uma composiÇço de revestimento
WO2005056759A3 (en)	2005-09-15	Methods of generating variant proteins with increased host string content and compositions thereof
EA200701065A1 (ru)	2007-12-28	Инъецируемые составы, содержащие нанодисперсный оланзапин
PA8567001A1 (es)	2003-12-10	Composicion de ziprasidona y controles sinteticos
WO2008057550A3 (en)	2009-04-02	Stabilization of vaccines by lyophilization
UA86591C2 (ru)	2009-05-12	Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
TW200738751A (en)	2007-10-16	Anti-EphrinB2 antibodies and methods using same
MXPA05008960A (es)	2005-11-04	Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
MEP34308A (en)	2011-02-10	Oral formulations of cladribine